(J Clin Endocrinol Metab 81: 1780-1783, 1996) M EDULLARY THYROID carcinoma (MTC) may occur as part of the autosomal dominant, inherited, multiple endocrine neoplasia type 2 (MEN 2) syndromes. Three hereditary forms of MEN 2 are known: MEN 2A is characterized by MTC in virtually 100% of patients, pheochromocytoma (pheo) in about 50% of patients, and/or primary hyperparathyroidism (pHpt) in about 20% of patients. The MEN 2B syndrome consists of MTC, pheo, mucosal neuromas, ganglioneuromatosis of the gut, and marfanoid habitus. The MTC only syndrome [also known as familial MTC (F'MTC)] is not associated with other endocrinopathies, and inherited predisposition to MTC is the only disease feature (1) .
Germline mutations of the ret protooncogene have been identified as the underlying cause of the MEN 2 and FMTC syndromes (2) (3) (4) (5) (6) . ret is a member of the family of receptor tyrosine kinases and is expressed in tissues derived from neural crest. Mutations at one of five codons for cysteine in the ret extracellular domain occur in MEN 2A and FMTC; MEN 2B is associated with a mutation of codon 918 in the intracellular tyrosine kinase domain of ret (7-10). These mutations convert ret into a dominant transforming gene (11). Identification of mutated gene carriers by DNA analysis allows earlier identification of subjects at risk in this familial cancer syndrome and provides the basis for preventative thyroidectomy (12, 13) .
Recently, two studies (3, 5) showed an association between disease phenotype and the nature and position of the ret mutation. Although there is some overlap, mutations in cysteine 634 are more strongly associated with MEN 2A than are mutations of cysteines farther from the cell membrane, which tend to occur in families with FMTC. Moreover, it has been suggested that patients with a Cys634-Arg substitution have a greater risk of developing parathyroid disease (3), but this 
Results
We identified point mutations including two insertions in all but one MEN 2A families. In 48 of 59 families (81%), mutations were detected at codon 634 (exon 11; Table 3 ). In 10 (17%) of the 59 MEN 2A families, a mutation at exon 10 was found. At codon 634, the most frequent base change found in MEN 2A was TGC to CGC, which altered the amino acid sequence from cysteine to arginine. This mutation was found in 22 of 59 (37%) families (Table 4) .
Extraction
of genomic DNA and amplification of exons 10, 11, and 16 from the ret protooncogene Genomic DNA was isolated using the QIAMP blood kit (Qiagen, Hilden, Germany). PCR amplifications were carried out with the oligonucleotide primer Retl9S (5'-GCAG-CATTGTTGGGGGACA-3') and RetlORb (5'-GTCCCGGCCACCCACT-3') for exon 10 (size of amplified fragment 140 bp), Ret20S (5'~CATGAGGCAGAGCATACGCA-3') and Ret2C (5'-GACAGCAGCACCGAGACGAT-3') for exon ll(156 bp), and rRet16 and fRetl6 (5'-AGGGAT-AGGG-CCTGGGCTTC3') for exon 16 (192 bp By contrast, mutations in exon 11 were detected in 14 of 27 (52%) FMTC families and in exon 10 in 12 of 27 (44%) F'MTC families (Table 3) . Thus, the prevalence of mutations at codon 634 is higher in MEN 2A families (81%) than in FMTC families (52%; P < 0.008, by Fisher's exact test, two-tail).
In F'MTC, the position and type of mutation were more heterogeneous, suggesting a correlation between the position and the type of mutation and the spectrum of tissues involved. To test this, we correlated the presence of pheo or pHpt and mutations at codon 634 in all MEN 2A and FMTC families. The data in Table 5 show a strong association (P < 0.004) between any mutation at codon 634 and the presence of pheo, but no association between the occurrence of pheo and any specific mutation at codon 634. The data in Table 6 show an association between a mutation in codon 634 and the presence of parathyroid disease, but no association between pHpt and any specific mutation at codon 634. (2, 3, 5, 6, (14) (15) (16) . These mutations converted the cysteines at codons 609, 618, 620 (all in exon lo), or 634 (in exon 11) to other amino acids. In our MEN 2A series, codon 611 was not affected. The types of mutations were very similar to those described in previous studies (3, 5) . The most frequent mutation in MEN 2A is located at codon 634, representing 83% of all disease mutations in our series and 84-94% in recent studies (3, 5) . The substitution of arginine at codon 634 represents the most frequent event of all changes at this codon: 38% in our series and 4654% in recent work (3, 5) . Some 96% of German FMTC families have mutations compared to 67-86% reported previously (3, 5, 17) ; 52% of mutations affect exon 11, and 44% affect exon 10. There is a strong correlation between the position of the mutation and disease phenotype; mutations in exon 11 (codon 634) are more strongly associated with MEN 2A than are mutations farther from the cell membrane (exon lo), which tend to occur in families with FMTC. Mutations elsewhere in ret may be responsible for the remaining few MEN 2A and FMTC families who do not have exon 10 or 11 mutations. For example, a mutation in ret exon 13 (codon 768), which codes for (19) . The same is true for parathyroid disease, as, despite identical mutations, MTC can be associated in some families with either parathyroid disease or pheo and in others with both diseases.
A codon 634 cysteine to arginine mutation does not predict parathyroid disease Any mutation at codon 634 was more likely to be associated with pheo or parathyroid disease. This is identical to other reports (3, 5) , in which there was a high prevalence of pheo (87% and 58%, respectively) in families with codon 634 mutations. German results do not support the earlier report of Mulligan et al. (9) , who found a codon 634 cysteine to arginine mutation to be predictive of parathyroid disease. Only 32% of German families with codon 634 cysteine to arginine mutations had parathyroid disease [88% in Mulligan's series (3) and 41% in Schuffenecker's (5)]. Therefore, German results mirror those of Schuffenecker et al. (5) . The discordance between our results and those of Mulligan might be explained by 1) the low number of families with pHpt in both studies; 2) the exclusion of one third of all families for statistical analysis because of a lack of documented screening for parathyroid disease in the Mulligan study, and/or 3) the result of a founder effect leading to a relatively high prevalence of a codon 634 CGC mutation in a particular population.
In all but one of our seven patients with MEN 2B, there was a single identical point mutation at codon 918, a substitution of methionine by threonine in the catalytic core region of the tyrosine kinase domain. In only one familial case displaying the typical clinical features of MEN 2B was no mutation in codon 918 found; in this case no mutation in exons 10 and 11 was identified.
This suggests that a mutation at codon 918 is crucial for ret gene function. Recent results show that the MEN 2B mutation altered ret catalytic properties both quantitatively and qualitatively, thus altering the substrate specificity of ret (11). Therefore, a mutation at codon 918 of the ret gene is the most prevalent genetic defect causing MEN 2B, but rare MEN 2B cases are associated with different mutations that have yet to be defined.
Conclusion
Three clinically distinct, autosomal dominant, inherited conditions involving MTC have been associated with germline mutations in ret. These three syndromes, MEN 2A, MEN 2B, and EMTC, involve different tissues in different combinations. We found a significant correlation between a particular syndrome, and thus the spectrum of tissues involved, and the site of the mutation. The ret 918 mutation is exclusively seen in MEN 2B syndrome; the ret 634 mutation is preferentially associated with MEN 2A and is strongly predictive of pheo and parathyroid disease.
Addendum
Meanwhile in the genetically unclassified MEN 2A family, a missense germline mutation in exon 13, and in the FMTC family in exon 14 could be detected, though the number of families with unidentified mutations decreased to one MEN 2B family. Tsai M-S, Ledger GA, Khosla S, Gharib H, Thibodeau SN. 
